Skip to main content
NCBI home page
Gut logoLink to Gut
. 1999 Sep;45(3):382–388. doi: 10.1136/gut.45.3.382

Predicting therapeutic outcome in severe ulcerative colitis by measuring in vitro steroid sensitivity of proliferating peripheral blood lymphocytes

S Hearing 1, M Norman 1, C Probert 1, N Haslam 1, C Dayan 1
PMCID: PMC1727659  PMID: 10446106

Abstract

BACKGROUND—Up to 29% of patients with severe ulcerative colitis (UC) fail to respond to steroid treatment and require surgery. Previous studies have failed to show a clear correlation between failure of steroid treatment in severe UC and measures of disease severity. The reasons for treatment failure therefore remain unknown.
AIM—To investigate the hypothesis that patients with severe UC who fail to respond to steroid treatment have steroid resistant T lymphocytes.
METHODS—Eighteen patients with severe UC were studied. After seven days' treatment with high dose intravenous steroids they were classified as complete responders (CR), incomplete responders (IR), or treatment failures (TF). Within 48 hours of admission blood was taken and the antiproliferative effect of dexamethasone on phytohaemagglutinin stimulated peripheral blood T lymphocytes was measured. Maximum dexamethasone induced inhibition of proliferation (Imax) was measured.
RESULTS—In vitro T lymphocyte steroid sensitivity of TF and IR patients was significantly less than that of CR patients. Both TF and 3/5 IR patients had an Imax of less than 60%; all CR patients had an Imax of greater than 60%. No significant correlation was seen between response to treatment and disease severity on admission. When in vitro T lymphocyte steroid sensitivity was remeasured three months later, there was no difference between the groups.
CONCLUSIONS—Results suggest that T lymphocyte steroid resistance is an important factor in determining response to steroid treatment in patients with severe UC and may be more predictive of outcome than disease severity.


Keywords: glucocorticoids; lymphocytes; phytohaemagglutinin; predicting outcome; ulcerative colitis

Full Text

The Full Text of this article is available as a PDF (106.3 KB).

Figure 1  .

Figure 1  

Open in a new tab

Inhibition of phytohaemagglutinin stimulated T lymphocyte proliferation by dexamethasone for the different clinical response groups; error bars represent SEM. Thymidine counts (mean (SD)): complete responders 54 611 (28 620) cpm; patients not achieving complete response 54 046 (21 644) cpm (incomplete responders 49 385 (21 643) cpm, treatment failures 65 696 (3562) cpm).

Figure 2  .

Figure 2  

Open in a new tab

In vitro T lymphocyte steroid sensitivity on admission compared with clinical outcome in severe ulcerative colitis.    

Figure 3  .

Figure 3  

Open in a new tab

In vitro T lymphocyte steroid sensitivity at three months' follow up compared with initial clinical outcome in severe ulcerative colitis.    

Figure 4  .

Figure 4  

Open in a new tab

Definition of Imax and IC50 in steroid sensitive and resistant subjects compared with previously used method of calculating IC50. In steroid sensitive individuals IC50 is similar using both methods; however, when the individual is steroid resistant there is a large difference between the two methods.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adcock I. M., Lane S. J., Brown C. R., Lee T. H., Barnes P. J. Abnormal glucocorticoid receptor-activator protein 1 interaction in steroid-resistant asthma. J Exp Med. 1995 Dec 1;182(6):1951–1958. doi: 10.1084/jem.182.6.1951. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Alvarez J., Surs W., Leung D. Y., Iklé D., Gelfand E. W., Szefler S. J. Steroid-resistant asthma: immunologic and pharmacologic features. J Allergy Clin Immunol. 1992 Mar;89(3):714–721. doi: 10.1016/0091-6749(92)90379-g. [DOI] [PubMed] [Google Scholar]
  3. Beato M. Gene regulation by steroid hormones. Cell. 1989 Feb 10;56(3):335–344. doi: 10.1016/0092-8674(89)90237-7. [DOI] [PubMed] [Google Scholar]
  4. Carmichael J., Paterson I. C., Diaz P., Crompton G. K., Kay A. B., Grant I. W. Corticosteroid resistance in chronic asthma. Br Med J (Clin Res Ed) 1981 May 2;282(6274):1419–1422. doi: 10.1136/bmj.282.6274.1419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Carpani de Kaski M., Hodgson H. J. Rolling review: inflammatory bowel disease. Aliment Pharmacol Ther. 1993 Oct;7(5):567–579. doi: 10.1111/j.1365-2036.1993.tb00134.x. [DOI] [PubMed] [Google Scholar]
  6. Chakravarty B. J. Predictors and the rate of medical treatment failure in ulcerative colitis. Am J Gastroenterol. 1993 Jun;88(6):852–855. [PubMed] [Google Scholar]
  7. Corrigan C. J., Brown P. H., Barnes N. C., Szefler S. J., Tsai J. J., Frew A. J., Kay A. B. Glucocorticoid resistance in chronic asthma. Glucocorticoid pharmacokinetics, glucocorticoid receptor characteristics, and inhibition of peripheral blood T cell proliferation by glucocorticoids in vitro. Am Rev Respir Dis. 1991 Nov;144(5):1016–1025. doi: 10.1164/ajrccm/144.5.1016. [DOI] [PubMed] [Google Scholar]
  8. Elson C. O. The basis of current and future therapy for inflammatory bowel disease. Am J Med. 1996 Jun;100(6):656–662. doi: 10.1016/s0002-9343(96)00049-6. [DOI] [PubMed] [Google Scholar]
  9. Forbes A. Frequency and significance of proximal extension of distal ulcerative colitis. Eur J Gastroenterol Hepatol. 1996 Jun;8(6):543–544. doi: 10.1097/00042737-199606000-00008. [DOI] [PubMed] [Google Scholar]
  10. Frey B. M., Frey F. J. Clinical pharmacokinetics of prednisone and prednisolone. Clin Pharmacokinet. 1990 Aug;19(2):126–146. doi: 10.2165/00003088-199019020-00003. [DOI] [PubMed] [Google Scholar]
  11. Griffin M. G., Miner P. B. Review article: refractory distal colitis -- explanations and options. Aliment Pharmacol Ther. 1996 Feb;10(1):39–48. doi: 10.1111/j.1365-2036.1996.tb00175.x. [DOI] [PubMed] [Google Scholar]
  12. Iida S., Gomi M., Moriwaki K., Itoh Y., Hirobe K., Matsuzawa Y., Katagiri S., Yonezawa T., Tarui S. Primary cortisol resistance accompanied by a reduction in glucocorticoid receptors in two members of the same family. J Clin Endocrinol Metab. 1985 May;60(5):967–971. doi: 10.1210/jcem-60-5-967. [DOI] [PubMed] [Google Scholar]
  13. Kam J. C., Szefler S. J., Surs W., Sher E. R., Leung D. Y. Combination IL-2 and IL-4 reduces glucocorticoid receptor-binding affinity and T cell response to glucocorticoids. J Immunol. 1993 Oct 1;151(7):3460–3466. [PubMed] [Google Scholar]
  14. Kirkham B. W., Corkill M. M., Davison S. C., Panayi G. S. Response to glucocorticoid treatment in rheumatoid arthritis: in vitro cell mediated immune assay predicts in vivo responses. J Rheumatol. 1991 Jun;18(6):821–825. [PubMed] [Google Scholar]
  15. Langhoff E., Ladefoged J., Jakobsen B. K., Platz P., Ryder L. P., Svejgaard A., Thaysen J. H. Recipient lymphocyte sensitivity to methylprednisolone affects cadaver kidney graft survival. Lancet. 1986 Jun 7;1(8493):1296–1297. doi: 10.1016/s0140-6736(86)91220-1. [DOI] [PubMed] [Google Scholar]
  16. Lichtiger S., Present D. H., Kornbluth A., Gelernt I., Bauer J., Galler G., Michelassi F., Hanauer S. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994 Jun 30;330(26):1841–1845. doi: 10.1056/NEJM199406303302601. [DOI] [PubMed] [Google Scholar]
  17. Paliogianni F., Raptis A., Ahuja S. S., Najjar S. M., Boumpas D. T. Negative transcriptional regulation of human interleukin 2 (IL-2) gene by glucocorticoids through interference with nuclear transcription factors AP-1 and NF-AT. J Clin Invest. 1993 Apr;91(4):1481–1489. doi: 10.1172/JCI116353. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Schreiber S., MacDermott R. P., Raedler A., Pinnau R., Bertovich M. J., Nash G. S. Increased activation of isolated intestinal lamina propria mononuclear cells in inflammatory bowel disease. Gastroenterology. 1991 Oct;101(4):1020–1030. doi: 10.1016/0016-5085(91)90729-5. [DOI] [PubMed] [Google Scholar]
  19. Schüle R., Rangarajan P., Kliewer S., Ransone L. J., Bolado J., Yang N., Verma I. M., Evans R. M. Functional antagonism between oncoprotein c-Jun and the glucocorticoid receptor. Cell. 1990 Sep 21;62(6):1217–1226. doi: 10.1016/0092-8674(90)90397-w. [DOI] [PubMed] [Google Scholar]
  20. Shanahan F. Pathogenesis of ulcerative colitis. Lancet. 1993 Aug 14;342(8868):407–411. doi: 10.1016/0140-6736(93)92818-e. [DOI] [PubMed] [Google Scholar]
  21. TRUELOVE S. C., WITTS L. J. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955 Oct 29;2(4947):1041–1048. doi: 10.1136/bmj.2.4947.1041. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Travis S. P., Farrant J. M., Ricketts C., Nolan D. J., Mortensen N. M., Kettlewell M. G., Jewell D. P. Predicting outcome in severe ulcerative colitis. Gut. 1996 Jun;38(6):905–910. doi: 10.1136/gut.38.6.905. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Truelove S. C., Willoughby C. P., Lee E. G., Kettlewell M. G. Further experience in the treatment of severe attacks of ulcerative colitis. Lancet. 1978 Nov 18;2(8099):1086–1088. doi: 10.1016/s0140-6736(78)91816-0. [DOI] [PubMed] [Google Scholar]
  24. Walker K. B., Potter J. M., House A. K. Interleukin 2 synthesis in the presence of steroids: a model of steroid resistance. Clin Exp Immunol. 1987 Apr;68(1):162–167. [PMC free article] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES